For Medical Professionals

Heart Failure Management System (HFMS)

Heart Failure Management System

Reduce heart failure readmissions and improve patient outcomes

Research published in JACC Heart Failure show that the novel Heart Failure Management System* (HFMS) reduces 90-day hospital readmission by 38%.¹

CONTACT A PRODUCT EXPERT

woman siting outside with ZOLL Heart Failure Management Patch overlay

Peer-reviewed clinical trial outcomes

Published in JACC Heart Failure, results from the Benefits of MicroCor in Ambulatory Decompensated Heart Failure (BMAD) Trial demonstrate that use of the Heart Failure Management System* (HFMS) reduces 90-day heart failure readmissions by 38%. Follow up results show a lasting 29% readmission reduction out to 1-year.²

EXPLORE HFMS OUTCOMES

Primary Endpoint graph displaying a 38% 90-day relative risk reduction in HF readmissions

1-year results of the Benefits of MicroCor in Ambulatory Decompensated Heart Failure (BMAD) trial demonstrate that the use of ZOLL Heart Failure Management System* (HFMS) in clinical practice reduces heart failure readmissions by 29% at one year.

Illustration of pulmonary fluid measured by radar waves emitting from ZOLL Heart Failure Management System (HFMS) patch

Detect fluid changes before signs and symptoms appear

ZOLL HFMS is a non-invasive, patch-based solution that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase of which is an early indicator of heart failure decompensation.

Radar waves can be used to measure interstitial edema, an early sign of heart failure
Changes in signal path delay and strength indicate changes in fluid
Waves are highly modulated by tissue hydration, producing a very sensitive, robust measurement known as Thoracic Fluid Index (TFI)

Radiofrequency signals propagate through the lungs. Proprietary HFMS algorithms determine patient-specific changes in pulmonary fluid levels, before signs and symptoms begin.

Timely alerts enable your action

Certified technicians from the ZOLL^® Independent Diagnostic Testing Facility (IDTF) analyze your patients’ HFMS data. The data can aid in the diagnosis and intervention for various clinical conditions, allowing for timely intervention.

ZOLL HFMS also captures additional patient data, including heart rate, activity, posture, and heart rhythm (ECG), that can be used to inform care plans.

Research published in JACC Heart Failure confirms that using HFMS significantly reduces 90-day readmissions following an acute decompensation event.

Graph displaying indicators of heart failure decompensation before an index heart failure event, displaying that pulmonary fluid occurs before weight and symptoms

Pulmonary Fluid: An early indicator of decompensation

Pulmonary fluid can accumulate days before patients experience noticeable symptoms and can be an early indicator of a heart failure decompensation event.³

~1 in 3 heart failure patients are readmitted within 3 months⁴
Annual hospitalizations for heart failure exceed 1M patients⁵
90% of annual hospitalizations are due to fluid overload⁶

Patient profile & workflow management

ZOLL HFMS may benefit patients who:

Have had an acute event for volume overload and have been effectively diuresed, are now stable, and will benefit from remote pulmonary fluid management to predictively prevent a recurrent hospitalization
Have intermittent and/or poorly controlled dyspnea, orthopnea, edema, or other fluid overload-related symptoms
Require GDMT pharmaceutical titration to control fluid overload

Case Study

Defining an Effective Workflow for ZOLL HFMS

From Andrew Darlington, DO, FACC Cardiology, Advanced Heart Failure and Transportation, Piedmont Heart Institute (Fayetteville, GA), find insights and strategies for integrating the ZOLL Heart Failure Management System into clinical practice

VIEW CASE STUDY

Preview icon for ZOLL Heart Failure Management System Case Study titled “Defining an Effective Workflow for Integrating the ZOLL Heart Failure Management System into Clinical Practice”

Frequently Asked Questions

What is ZOLL HFMS?

ZOLL HFMS is a non-invasive, patch-based device that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase of which is an early indicator of heart failure decompensation.

ZOLL HFMS also records, stores, and transmits additional patient data including heart rate, respiration rate, activity, posture, and heart rhythm (ECG) that can be used to inform care plans.

What type of patient is ZOLL HFMS appropriate for?

ZOLL HFMS may benefit patients who:

Have an acute event for volume overload and have been effectively diuresed, are now stable, and will benefit from remote pulmonary fluid management to predictively prevent a recurrent hospitalization
Have intermittent and/or poorly controlled dyspnea, orthopnea, edema, or other fluid overload-related symptoms
Require GDMT pharmaceutical titration to control fluid overload

ZOLL HFMS may not benefit patients who:

Are currently experiencing symptomatic volume overload and/or are considered “wet”
Have their fluid status being actively monitored by an implanted device
Do not meet indications for use⁺

Is ZOLL HFMS covered by insurance?

ZOLL is currently accepting patients with all Medicare and most commercial insurances.

Support for you and your patients

From prescription to timely alerts, ZOLL supports every step of the process so that your team can focus on optimizing care and improving outcomes.

Educational videos

Short, effective videos help your patients understand heart failure and learn how to use and care for ZOLL HFMS.

Patient Videos

Illustration depicting Delivery of ZOLL HFMS

Patient set-up

ZOLL ships HFMS to your patient and contacts them directly to help them set up the device.

Contact ZOLL anytime

Patients can call ZOLL 24/7 at 1-888-592-3798 or email us at CardiacSupport@zoll.com.

^*FDA registered name: μCor Heart Failure and Arrhythmia Management System
+See ZOLL μCor Heart Failure and Arrhythmia Management System Clinical Manual for Indications for Use.

Boehmer, J, Cremer, S, Abo-Auda, W. et al. Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial.  J Am Coll Cardiol HF. 2024 Dec, 12 (12) 2011–2022.
Boehmer, J. (2025) Reduced heart failure rehospitalization at 1 year for patients wearing a radiofrequency based sensor [Abstract]. In Proceedings of the THT 2025 Conference. Boston, MA. https://www.jacc.org/doi/10.1016/j.jchf.2024.07.022
Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009 Dec;6(4):287-92
Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail. 2021;14(4):e008335.
Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol. 2017;69(19):2428-2445.
Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-854.